Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11617MR)

This product GTTS-WQ11617MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus; Humanized
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11617MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15002MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ13500MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ248MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ11015MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ6714MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ8590MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ1702MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ753MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AAB-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW